Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
Date:3/3/2010

"We were pleased to report a particularly strong quarter for product sales, which was driven by the continued strong performance of our Proprietary Medical Products, where we saw sales growth of 53% compared to the same period in 2008," said Dr. William Hunter, President and CEO of Angiotech. "We are particularly pleased by the continued success of our Quill(TM) SRS product line, which we believe will continue to be a strong performer during 2010."

    Fourth Quarter Financial Highlights

    -   Total revenue was $63.6 million.

    -   Net product sales were $50.0 million. Sales of our Proprietary
        Medical Products were $18.3 million, or 37% of total product sales.
        Sales of our Base Medical Products were $31.7 million, or 63% of
        total product sales.

    -   Royalty revenue was $13.5 million.

    -   Research and development expenses were $6.2 million.

    -   Selling, general and administrative expenses were $22.4 million.

    -   Net loss and net loss per share were $15.6 million and $0.18,
        respectively.

    -   As of December 31, 2009, cash and short-term investments were
        $57.3 million and net debt was $517.7 million.

    Selected Non-GAAP Financial Measures

    -   Certain financial measures in this press release are prepared in
        accordance with United States Generally Accepted Accounting
        Principles ("GAAP"). In addition, certain financial measures
        presented below and in the appendix to this press release are non-
        GAAP, or adjusted, financial measures that exclude certain items.
        Management uses certain non-GAAP, or adjusted, financial measures to
        establish operational goals, and believes that these measures may
        assist investors in evaluating the results of our business and
        analyzing the underlying trends in our business over time. Investors
        should consider these non-GAAP adjusted financial measures in
   
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
3. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
4. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
5. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
6. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
7. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
8. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
9. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
10. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
11. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Investor-Edge has initiated coverage on ... Medivation Inc. (NASDAQ: MDVN ), Pharmacyclics Inc. ... MKT: SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free ... http://investor-edge.com/register . On Wednesday, October 29, ... the Dow Jones Industrial Average declined 0.18%, to finish ...
(Date:10/30/2014)... UK (PRWEB) October 29, 2014 Global ... of the world economic crisis during 2008-2009, especially in ... has recovered and currently is keeping to a growing ... output volume is utilized in the construction segment. In ... of pipes, profiles, tubing, sheets and rigid film. Moreover, ...
(Date:10/30/2014)... On October 26th at the Mid ... leading applied stem cell research scientist Neil Riordan, ... talks on New Techniques for Enhancing Stem Cell ... Cells. , Dr. Riordan focused on historical medical ... AlphaGEMS that include: wound healing; inflammation and pain ...
(Date:10/30/2014)... 2014 Rancho BioSciences , the ... manually curated public data source TCGA for ... the data is now available for other oncology groups. ... and internal data sources for their Pharma, Government and ... the data that becomes more easily accessible. Rancho ...
Breaking Biology Technology:Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Rancho BioSciences Manually Curated TCGA Data Sets Available 2
... leading innovator in the development and commercialization of sensing systems ... (CBRNE) materials, today announced a media awareness initiative for JMAR,s ... online system for real-time detection of pathogens in water. ... ...
... release of GridGain 2.1 - the next version of its innovative ... ... January 13, 2009 -- GridGain Systems is proud to ... its innovative Java-based Open Cloud Platform. GridGain 2.1 provides the industry ...
... Coronary StentForms Alliance to Jointly Develop Drug Eluting ... announced today that that the company entered into ... incorporated subsidiary of Opto Circuits (OCI) Ltd., by ... Maxcor,s Genius MAGIC Cobalt Chromium Coronary Stent System ...
Cached Biology Technology:JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism 2JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism 3JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism 4GridGain 2.1 - Open Cloud Platform Enables Development of Native Cloud Applications 2GridGain 2.1 - Open Cloud Platform Enables Development of Native Cloud Applications 3Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons 2Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons 3
(Date:10/31/2014)... in cities is good for attracting species, but it may ... University of Iowa study has found. , The researchers surveyed ... and recorded the abundance of two insects that interact with ... trees, black cherry and black walnut, they didn,t find a ... that feed on the walnuts and black cherries and a ...
(Date:10/31/2014)... been studying the behavior of approximately 300 wild ... They observed that ravens slowly build alliances through ... they also observed that these affiliative interactions were ... about 50 % of the cases these interventions ... ravens, intervening can be potentially risky when the ...
(Date:10/30/2014)... LANSING, Mich. – When most animals begin life, cells ... or a vital organ. However, mammals, including humans, are ... a different first choice – to become the protective ... It,s during this critical first step that research from ... published in the current issue of PLOS ...
Breaking Biology News(10 mins):Green spaces don't ensure biodiversity in urban areas 2Identifying the source of stem cells 2
... Nelson Laboratories ( www.nelsonlabs.com ) will offer free ... in San Jose, CA ... Those interested in a consultation should register at ... Rollins will also present, "Selection, Testing and Validation ...
... Wilhoit and Timothy Coolong from the University of Kentucky ... application of organic mulches more efficient. The research team ... in the August issue of HortTechnology . The ... to document its efficiency. "We modified an unroller so ...
... Why do crosses between closely related species fail to ... Axel Imhof of Ludwig-Maximilians-Universitaet (LMU) in Munich shows that ... - of certain key proteins are crucial in mediating ... to the same biological species, if matings between them ...
Cached Biology News:Nelson Laboratories to Offer Free Biocompatibility Consultations During BIOMEDevice San Jose 2New bale unroller design deemed effective 2Origin of species: Protein imbalances doom hybrids 2
... dUTPase The thermostable dUTPase(pyrococcus ... PCR (using proofreading DNA polymerases). ... PCR reactions and dNTP solutions. ... proofreading DNA polymerase reaction can prevent ...
... an exciting product for cell-based kinetic assays ... the use of expensive HTS equipment, which ... the assay development stage. The NOVOstar offers ... as well as any other assay suitable ...
... save space and organize gloves, ... other garb. They are the ... small parts used in labs, ... Open-slot design for easy cleaning. ...
... Agilent Technologies introduces an enhanced ... ICP-MS for Windows 2000 and ... From September 2003, all new ... controlled by the new ChemStation ...
Biology Products: